Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and maintains the target price at $46.
According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The valuation of Neurogene's shares is now closely aligned with its cash reserves following disclosures of a Serious Adverse Event in its NGN-401 high dose trial and the termination of the Battens program on November 11. Despite these setbacks, the company's management remains optimistic, not anticipating a clinical hold, as discussions with the FDA have suggested the safety of the low-dose option.
The firm revised its projections for third quarter 2024 earnings and incorporated the effects of a trial participant landing in critical condition following a high dose of NGN-401. This adjustment in analysis further influenced the expected market share for NGN-401 in the Rett syndrome gene therapy market, now estimated at 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析师Paul Matteis维持$Neurogene (NGNE.US)$买入评级，维持目标价46美元。
根据TipRanks数据显示，该分析师近一年总胜率为39.5%，总平均回报率为2.2%。
此外，综合报道，$Neurogene (NGNE.US)$近期主要分析师观点如下：
Neurogene股票的估值现在与其现金储备紧密对齐，因为NGN-401高剂量试验出现严重不良事件并于11月11日终止巴顿计划的披露。尽管遇到这些挫折，公司管理层仍然乐观，不预期会有临床持有，在与FDA的讨论中表明低剂量选择的安全性。
该公司修订了2024年第三季度收益预测，并纳入了一名试验参与者因NGN-401高剂量导致重症的影响。这一分析调整进一步影响了Rett综合症基因治疗市场中NGN-401的预期市场份额，目前估计为50%。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
